F4-neuroprostanes mediate neurological severity in Rett syndrome

Clinica Chimica Acta

Volumn 412, Issue 15-16, 2011, Pages 1399-1406

  Signorini, Cinzia ^a   De Felice, Claudio ^b   Leoncini, Silvia ^a   Giardini, Anna ^a   D'Esposito, Maurizio ^c,d   Filosa, Stefania ^c,d   Della Ragione, Floriana ^c,d   Rossi, Marcello ^b   Pecorelli, Alessandra ^a   Valacchi, Giuseppe ^a,e   Ciccoli, Lucia ^a   Hayek, Joussef ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

^c INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^d IRCCS NEUROMED   (Italy)

^e Kyung Hee University   (South Korea)

Author keywords

3 polyunsaturated fatty acids; Autism spectrum disorders; CDKL5; MeCP2; Neuroprostanes; Rett syndrome

Indexed keywords

F4 NEUROPROSTANE; NEUROPROSTANE; OMEGA 3 FATTY ACID; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; ISOPROSTANE DERIVATIVE; MECP2 PROTEIN, HUMAN; METHYL CPG BINDING PROTEIN 2;

ADOLESCENT; ADULT; ARTICLE; BLOOD LEVEL; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG RESPONSE; F4 NEUROPROSTANE BLOOD LEVEL; FEMALE; GAS CHROMATOGRAPHY; GENE; HUMAN; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; METHYL CPG BINDING PROTEIN 2 GENE; MISSENSE MUTATION; NEUROLOGIC DISEASE; NONSENSE MUTATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETT SYNDROME; BLOOD; COHORT ANALYSIS; GENETICS; MUTATION; NEUROLOGIC EXAMINATION; PRESCHOOL CHILD;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; ISOPROSTANES; METHYL-CPG-BINDING PROTEIN 2; MUTATION; NEUROLOGIC EXAMINATION; RETT SYNDROME; YOUNG ADULT;

EID: 79956316620     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.04.016     Document Type: Article

References (53)

1. Chahrour M., Zoghbi H.Y. The story of Rett syndrome: from clinic to neurobiology. Neuron 2007, 56:422-437.
2. Moss J., Howlin P. Autism spectrum disorders in genetic syndromes: implications for diagnosis, intervention and understanding the wider autism spectrum disorder population. J Intellect Disabil Res 2009, 53:852-873.
3. Miltenberger-Miltenyi G., Laccone F. Mutations and polymorphisms in the human methyl CpG-binding protein MECP2. Hum Mutat 2003, 22:107-115.
4. Christodoulou J., Grimm A., Maher T., Bennetts B. RettBASE: the IRSA MECP2 variation database-a new mutation database in evolution. Hum Mutat 2003, 21:466-472.
5. Neul J.L., Kaufmann W.E., Glaze D.G., et al. Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol 2010, 68:944-950.
6. Hagberg B. Clinical manifestations and stages of Rett syndrome. Ment Retard Dev Disabil Res Rev 2002, 8:61-65.
7. Halliwell B., Gutteridge J.M.C. Free radicals, other reactive species and disease. Free radicals in biology and medicine 1999, 617-783. Clarendon Press, Oxford. B. Halliwell, J.M.C. Gutteridge (Eds.).
8. Seet R.C., Lee C.Y., Lim E.C., et al. Oxidative damage in Parkinson disease: measurement using accurate biomarkers. Free Radic Biol Med 2010, 48:560-566.
9. De Felice C., Ciccoli L., Leoncini S., et al. Systemic oxidative stress in classic Rett syndrome. Free Radic Biol Med 2009, 47:440-448.
10. Sierra C., Vilaseca M.A., Brandi N., et al. Oxidative stress in Rett syndrome. Brain Dev 2001, 23:236-239.
11. Montuschi P., Barnes P., Roberts L.J. Insights into oxidative stress: the isoprostanes. Curr Med Chem 2007, 14:703-717.
12. Roberts L.J., Montine T.J., Markesbery W.R., et al. Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J Biol Chem 1998, 273:13605-13612.
13. Taber D.F., Roberts L.J. Nomenclature systems for the neuroprostanes and for the neurofurans. Prostaglandins Other Lipid Mediat 2005, 78:14-18.
14. Sampieri K., Meloni I., Scala E., et al. Italian Rett database and biobank. Hum Mutat 2007, 28:329-335.
15. Neul J.L., Fang P., Barrish J., et al. Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome. Neurology 2008, 70:1313-1321.
16. Signorini C., Ciccoli L., Leoncini S., et al. Free iron, total F2-isoprostanes and total F4-neuroprostanes in a model of neonatal hypoxic-ischemic encephalopathy: neuroprotective effect of melatonin. J Pineal Res 2009, 46:148-154.
17. Montine T.J., Quinn J.F., Milatovic D., et al. Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease. Ann Neurol 2002, 52:175-179.
18. Amir R.E., Van den Veyver I.B., Schultz R., et al. Influence of mutation type and X chromosome inactivation on Rett syndrome phenotypes. Ann Neurol 2000, 47:670-679.
19. Cheadle J.P., Gill H., Fleming N., et al. Long-read sequence analysis of the MECP2 gene in Rett syndrome patients: correlation of disease severity with mutation type and location. Hum Mol Genet 2000, 9:1119-1129.
20. Huppke P., Laccone F., Kramer N., Engel W., Hanefeld F. Rett syndrome: analysis of MECP2 and clinical characterization of 31 patients. Hum Mol Genet 2000, 9:1369-1375.
21. Weaving L.S., Williamson S.L., Bennetts B., et al. Effects of MECP2 mutation type, location and X-inactivation in modulating Rett syndrome phenotype. Am J Med Genet 2003, 118A:103-114.
22. Bebbington A., Anderson A., Ravine D., et al. Investigating genotype-phenotype relationships in Rett syndrome using an international data set. Neurology 2008, 70:868-875.
23. Temudo T., Santos M., Ramos E., et al. Rett syndrome with and without detected MECP2 mutations: an attempt to redefine phenotypes. Brain Dev 2011, 33:69-76.
24. Leonard H., Colvin L., Christodoulou J., et al. Patients with the R133C mutation: is their phenotype different from patients with Rett syndrome with other mutations?. J Med Genet 2003, 40:e52.
25. D'Esposito M., Quaderi N.A., Ciccodicola A., et al. Isolation, physical mapping and northern analysis of the X-linked human gene encoding methyl CpG binding protein, MECP2. Mamm Genome 1996, 7:533-535.
26. Archer H.L., Evans J., Leonard H., et al. Correlation between clinical severity in patients with Rett syndrome with a p.R168X or p.T158M MECP2 mutation, and the direction and degree of skewing of X-chromosome inactivation. J Med Genet 2007, 44:148-152.
27. Sundelöf J., Kilander L., Helmersson J., et al. Systemic inflammation and the risk of Alzheimer's disease and dementia: a prospective population-based study. J Alzheimers Dis 2009, 18:79-87.
28. Gitschier J. On the tracks of DNA methylation: an interview to Adrian Bird. PLoS Genet 2009, 5:e1000667. 10.1371/journal.pgen.1000667.
29. Johnston M.V., Ishida A., Ishida W.N., Matsushita H.B., Nishimura A., Tsuji M. Plasticity and injury in the developing brain. Brain Dev 2009, 31:1-10.
30. Pecorelli A., Ciccoli L., Signorini C., et al. Increased levels of 4HNE-protein plasma adducts in Rett syndrome. Clin Biochem 2011, 44:368-371.
31. Renieri A., Mari F., Mencarelli M.A., et al. Diagnostic criteria for the Zappella variant of Rett syndrome (the preserved speech variant). Brain Dev 2009, 31:208-216.
32. Mari F., Azimonti S., Bertani I., et al. CDKL5 belongs to the same molecular pathway of MeCP2 and it is responsible for the early-onset seizure variant of Rett syndrome. Hum Mol Genet 2005, 14:1935-1946.
33. Carouge D., Host L., Aunis D., Zwiller J., Anglard P. CDKL5 is a brain MeCP2 target gene regulated by DNA methylation. Neurobiol Dis 2010, 38:414-424.
34. Guy J., Gan J., Selfridge J., Cobb S., Bird A. Reversal of neurological defects in a mouse model of Rett syndrome. Science 2007, 315:1143-1147.
35. Ogier M., Wang H., Hong E., Wang Q., Greenberg M.E., Katz D.M. Brain-derived neurotrophic factor expression and respiratory function improve after ampakine treatment in a mouse model of Rett syndrome. J Neurosci 2007, 27:10912-10917.
36. Roux J.C., Dura E., Moncla A., Mancini J., Villard L. Treatment with desipramine improves breathing and survival in a mouse model for Rett syndrome. Eur J Neurosci 2007, 25:1915-1922.
37. Tropea D., Giacometti E., Wilson N.R., et al. Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice. Proc Natl Acad Sci U S A 2009, 106:2029-2034.
38. Belayev L., Khoutorova L., Atkins K.D., et al. Docosahexaenoic acid therapy of experimental ischemic stroke. Transl Stroke Res 2011, 2:33-41.
39. Calder P.C., Yaqoob P. Understanding omega-3 polyunsaturated fatty acids. Postgrad Med 2009, 121:148-157.
40. Soderberg M., Edlund C., Kristensson K., Dallner G. Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids 1991, 26:421-425.
41. Serhan C.N., Gotlinger K., Hong S., et al. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes. J Immunol 2006, 176:1848-1859.
42. Simopoulos AP, in press. Evolutionary aspects of diet: the omega-6/omega-3 ratio and the brain. Mol Neurobiol. doi:10.1007/s12035-010-8162-0.
43. Hagiwara H, Nishiyama Y, Katayama Y, in press. Effects of eicosapentaenoic acid on asymmetric dimethylarginine in patients in the chronic phase of cerebral infarction: a preliminary study. J Stroke Cerebrovasc Dis. doi:10.1016/j.jstrokecerebrovasdis.2010.12.006.
44. Lintas C, Sacco R, Persico AM, in press Genome-wide expression studies in Autism spectrum disorder, Rett syndrome, and Down syndrome. Neurobiol Dis. doi:10.1016/j.nbd.2010.11.010.
45. Balagopalakrishna C., Manoharan P.T., Abugo O.O., Rifkind J.M. Production of superoxide from hemoglobin-bound oxygen under hypoxic conditions. Biochemistry 1996, 35:6393-6398.
46. Nagababu E., Ramasamy S., Rifkind J.M. Site-specific cross-linking of human and bovine hemoglobins differentially alters oxygen binding and redox side reactions producing rhombic heme and heme degradation. Biochemistry 2002, 41:7407-7415.
47. Ciccoli L., Rossi V., Leoncini S., et al. Iron release, superoxide production and binding of autologous IgG to band 3 dimers in newborn and adult erythrocytes exposed to hypoxia and hypoxia-reoxygenation. Biochim Biophys Acta 2004, 1672:203-213.
48. Morrow J.D., Hill K.E., Burk R.F., Nammour T.M., Badr K.F., Roberts L.J. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci U S A 1990, 87:9383-9387.
49. Wang H., Yuan G., Prabhakar N.R., Boswell M., Katz D.M. Secretion of brain-derived neurotrophic factor from PC12 cells in response to oxidative stress requires autocrine dopamine signaling. J Neurochem 2006, 96:694-705.
50. Pugazhenthi S., Phansalkar K., Audesirk G., West A., Cabell L. Differential regulation of c-jun and CREB by acrolein and 4-hydroxynonenal. Free Radic Biol Med 2006, 40:21-34.
51. Urdinguio R.G., Lopez-Serra L., Lopez-Nieva P., et al. Mecp2-null mice provide new neuronal targets for Rett syndrome. PLoS One 2008, 3:e3669.
52. Cardaioli E., Dotti M.T., Hayek G., Zappella M., Federico A. Studies on mitochondrial pathogenesis of Rett syndrome: ultrastructural data from skin and muscle biopsies and mutational analysis at mtDNA nucleotides 10463 and 2835. J Submicrosc Cytol Pathol 1999, 31:301-304.
53. Kriaucionis S., Paterson A., Curtis J., Guy J., Macleod N., Bird A. Gene expression analysis exposes mitochondrial abnormalities in a mouse model of Rett syndrome. Mol Cell Biol 2006, 26:5033-5042.